OM
CMPX icon

Opaleye Management’s Compass Therapeutics CMPX Stock Holding History

Opaleye Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,170,000
Closed -$6.28M – 52
2024
Q1 		$6.28M Buy
+3,170,000
New +$5.48M 1.37% 23

Other funds holding CMPX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Opaleye Management's CMPX Position: Q2 2024 in Review

Opaleye Management sold out of Compass Therapeutics (CMPX) in Q2 2024, closing a stake of 3,170,000 shares — an estimated $6.28M sold.

Opaleye Management first reported a position in CMPX in Q1 2024 and held it in 1 quarter. The position peaked at $6.28M in Q1 2024. 82 funds tracked by Wall St. Rank hold CMPX as of Q2 2024.

  • Opaleye Management reported no remaining Compass Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Opaleye Management sold 3,170,000 Compass Therapeutics shares in Q2 2024, an estimated $6.28M.
  • Opaleye Management first reported a position in Compass Therapeutics in Q1 2024 and held it in 1 quarter.
  • Opaleye Management's Compass Therapeutics position peaked at $6.28M in Q1 2024.
  • 82 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2024.

Based on Opaleye Management's 13F filing for Q2 2024, filed 14 Aug 2024.